Investigation of salivary and serum immunoglobulin, Cytokines, steroid hormone levels in breast cancer

Parween Abdulsamad Ismail


Objective: To study the serum and salivary levels of some Cytokines, immunoglobulin and  steroid hormone  in breast cancer in different pathological stages of the concentration.

 Methods: The study was conducted on newly-diagnosed breast cancer patients who had not received any treatment. Controls were women not known to have any breast disease or hormone-related tumours. A total of 75 patients with breast cancer were divided into stage I, II and III according to clinical pathology and 45 healthy subjects were selected as control group. Serum and salivary Cytokines(IL-6,TNF-α  and IL-8)   immunoglobulin (IgG and  IgA ,)  steroid hormone(Estrogen, Progesterone , Testosterone .,) levels were measured and compared of all subjects.

Results: The results demonstrated significantly high values of serum and salivary IgG, IgA ,TNF-α,IL-6  , IL-8  estrogen, progesterone, and  testosterone) (P=0.0001) P<0.05, p<0.01, p < 0.0001)  (p<0.001,p<0.01, p<0.05, ) respectively in breast cancer in comparison with control group.

Conclusion: An elevation of serum steroid hormone, immunoglobulins (IgA, IgG, IgM),and Cytokines levels in cases of carcinoma breast in this  study is signifies, and its importance as a marker of the breast cancer . Analyzing serum  and salivary cytokine ,steroid hormone and immunoglobulins levels might help identify patients with a poor prognosis who may benefit from more aggressive disease management.


Breast cancer, immunoglobulin, Cytokines, steroid hormone


Shannon B, Sarah G, Sarah H. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 2014; 34(3): 1071.

Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2015; 223(2): 308-318.

Qian Xiuzhen. Efficacy and prognosis analysis of different subtype of breast cancer. J Hainan Med Coll 2013; 19(12): 1743-1745.

Liu Chuanjin, Bao Qianqian, Zhou Jianyu. Relevant research between biological indexes expression of breast cancer and ultrasound contrast quantitative analysis. J Med Imaging 2017; 27(6): 1095.

. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development 1999;13:1382-1397.

. Singh B, Berry JA, Shoher A, et al. COX-2 induces IL-11 production in human breast cancer cells. Journal Of SurgicalResearch 2006;131:267-275.

. Singh RP, Singh VP, Udupa KN. E-Rosette forming lymphocytes and serum immunoglobulins in breast cancer patients. Materia Medica Polona (Polish Journal Of Medicine And Pharmacy) 1991;23:179-181.

. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.

. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al.

Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-44.

. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J.Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep. 2006;15(1):179-85.

. Esquivel-Velazquez M, Ostoa-Saloma P, Palacios-Arreola MI, Nava-Castro KE, Castro JI,

Morales-Montor J. The role of cytokines in breast cancer development and progression. J Interferon

Cytokine Res. 2015;35(1):1-16.

. Cho YA, Sung MK, Yeon JY, Ro J, Kim J. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res Treat.2013;45(3):210-9.

. Chavey C, Bibeau F, Gourgou-Bourgade S, BurlinchonS, Boissiere F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content.Breast Cancer Res. 2007;9(1):R15.

. Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138(3):657-64.

. Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N,Leider-Trejo L, Leibovich-Rivkin T, et al. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer.2011;11:130.

. Gangemi S, Minciullo P, Adamo B, Franchina T,Ricciardi GR, Ferraro M, et al. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem. 2012;113(6):2122-5.

.Sanguinetti A, Santini D, Bonafe M, Taffurelli M, Avenia N. Interleu¬kin-6 and pro inflammatory status in the breast tumor microenvi¬ronment. World J Surg Oncol. 2015;13:129.

. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382:673–682.

. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J. 2007;21:3763–3770.

.Saglam O, Unal ZS, Subasi C, Ulukaya E, Karaoz E. IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis. Tumour Biol. 2015;36:5667–5677.

.Di GH, Liu Y, Lu Y, Liu J, Wu C, Duan HF. IL-6 secreted from senescent mesenchymal stem cells promotes proliferation and migration of breast cancer cells. PLoS One. 2014;9:e113572

..Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentra¬tion of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–84.

..Kornasiewicz O, Grat M, Dudek K, Lewandowski Z, Gorski Z, Zienie¬wicz K, Krawczyk M. Serum levels of HGF, IL-6, and TGF-alpha after benign liver tumor resection. Adv Med Sci. 2015;60:173–177.

. Katanov C, Lerrer S, Liubomirski Y, et al. Regulation of the inflammato¬ry profile of stromal cells in human breast cancer: prominent roles for TNF-alpha and the NF-kappaB pathway. Stem Cell Res Ther. 2015;6:87 .

Alokail MS, Al-Daghri NM, Mohammed AK, Vanhoutte P, Alenad A. Increased TNF alpha, IL-6 and ErbB2 mRNA expression in periph¬eral blood leukocytes from breast cancer patients. Med Oncol. 2014;31:38.

. .Zhou XL, Fan W, Yang G, Yu MX. The clinical significance of PR, ER, NF-kappa B, and TNF- alpha in breast cancer. Dis Markers. 2014;2014:494581.

Todorovic-Rakovic N, Milovanovic J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013;33:563–570.

Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentra¬tion of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2003;48:82–84.

.Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 2000, 21(3):427-433.

-*Al-Dleemy W.K. (2005): Biochemical study of some parameters inbreast cancer patients. Ph.D Thesis college of science Mosul university.

-*Al-Mudhaffar S., &Al- Sammarai I.H. (2001): Evaluation of immunoglobulins, lactate dehydrogenase isoenzyme in breast cancer tumor patients Nat. J., Chem. 2:315-329

-Cochran A.J. (2002): The effect of cancer treatment on the immune system. Am. J. Cancer 38(7): 122-125

. Gendek-Kubiak H, Grzegorczyk J, Gendek EG, et al.Pre-operative levels of serum immunoglobulins,circulating immune complexes and complement proteins in patients with different

types of neoplasms. Archivum Immunologiae et Therapiae Experimentalis, 2001;49:S89-S95.

. Chen Z, Qiu X, Gu J. Immunoglobulin expression in nonlymphoid lineage and neoplastic cells. American Journal of Pathology 2009;174:1139-1148.

5. Qiu X, Zhu X, Zhang L, et al. Human epithelial cancers secrete immunoglobulin G with unidentified specificity to promote growth and survival of tumor cells. Cancer Research


Mohamed MM, El-Ghonaimy EA, Nouh MA. Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties. Int J Biochem Cell Biol 2014; 46(1): 138-147.

Matsumoto H, Koo S, Dent R. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 2015; 68(7): 506.

Katanov C, Lerrer S, Liubomirski Y. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway. Stem Cell Res Ther 2015; 6(1): 87.

Tripsianis G, Papadopoulou E, Anagnostopoulos K. Coexpression of IL-6 and TNF-α: prognostic significance on breast cancer outcome.Neoplasma 2014; 61(2): 205.

Maccio A, Madeddu C (2013). The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications - a review. J Mol Med (Berl), 91, 1355-68.

Ohishi W, Cologne JB, Fujiwara S, et al (2014). Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer, 134, 154-63

Lederle W, Depner S, Schnur S, et al (2011). IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int J Cancer, 128, 2803-14.

Bharadwaj U, Li M, Zhang R, Chen C, Yao Q (2007). Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res, 67, 5479-88

. Lacko A, Gistere kI, Matkows kR, et al. The prognostic role of tumor-infiltrating CD8+ T lymphocytes in breast cancer. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings

(Post-Meeting Edition), (May 20 Supplement) 2008;26:11024.

. Alimhojaeva LT. Pro and anti-inflammatory cytokines levels in patients suffering breast cancer. The Republican Research Center of Oncology, Ministr y of Health, Uzbekistan,2010;(1):21-24. (

. Rivas MA, Carnevale RP, ProiettiCJ, et al. TNF alpha acting on TNFR1 promotes breast cancer growth via P42/P44 MAPK, JNK, Akt And NF-Kappa B-dependent pathways. Expermintal Cell Research 2008;314:509-529.

. Chen X, ShuY, LiW, et al. TNF-alpha-induced metastasis gene changes in MCF-7 cells.Journal of Nanjing Medical University 2008;22:366-371.

. Jabłonska E, Kiluk M, Markiewicz W, et al. TNF-a, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. ArchivumImmunologiae et Therapiae-Experimentalis 2001;49:63-69.

. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 2001; 19: 683-765.

. Gado K, Domjan G, Hegyesi H, Falus A. Role of interleu¬kin-6 in the pathogenesis of multiple myeloma. Cell Biol Int, 2000; 24: 195-209.

. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res, 2000; 6: 2104-19.

. Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine, 2001; 16: 251-7.

. Kovacs E. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother, 2001; 55: 391-6.

. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer, 2000; 7: 187-90.

Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L. and Hoover R. 1998. “Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk”. Jama Middle East, 6(10): pp.68-74.

Herman A., Mazur W., Heinonen S.M. and Stumpf K. 2002. “Estrogens and breast cancer”. J. Biochem., 20(2): pp.527-529.

Al-Mudhaffar S. and Al-Samarai I.H. 2001. “Evaluation of immunoglobulins, lactate dehydrogenase isoenzyme in breast tumor patients”. Nat. J. Chem., 2: pp.315-329.

Lindsay R., Gallagher J.C., Kleerekoper U. and Pickar J.H. 2002. “Effect of lower doses of estrogen therapy for postmenopausal women”. Jama Middle East, 12(9): pp.74-84.

9]Halava H, Korhonen MJ, Huupponen R, Setoguchi S, Pentti J, Kivimaki M, et al. Lifestyle factors as predictors of nonad¬herence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ 2014,186:E449-456.

Danova M., Perotti C., Mora O. and Lacotti C. 1998. “Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer”. Oncol-Rep., 5(2): pp.9-427.

Stewart F.H., Harper C.C., Ellertson C.E. and Grimes D.A. 2001. “Clinical breast and pelvic examination requirements for hormonal contraception”. Jama Middle East, 11(7): pp.82-89.


  • There are currently no refbacks.